These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 8473998

  • 1. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
    Colzi A, D'Agostini F, Cesura AM, Borroni E, Da Prada M.
    J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998
    [Abstract] [Full Text] [Related]

  • 2. Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant.
    Colzi A, d'Agostini F, Cesura AM, Da Prada M.
    Psychopharmacology (Berl); 1992 Apr; 106 Suppl():S17-20. PubMed ID: 1546133
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Fuller RW, Hemrick-Luecke SK.
    J Pharmacol Exp Ther; 1985 Mar; 232(3):696-701. PubMed ID: 3871853
    [Abstract] [Full Text] [Related]

  • 4. Modification of the striatal dopaminergic neuron system by carbon monoxide exposure in free-moving rats, as determined by in vivo brain microdialysis.
    Hara S, Mukai T, Kurosaki K, Kuriiwa F, Endo T.
    Arch Toxicol; 2002 Oct; 76(10):596-605. PubMed ID: 12373456
    [Abstract] [Full Text] [Related]

  • 5. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition.
    Iurlo M, Leone G, Schilström B, Linnér L, Nomikos G, Hertel P, Silvestrini B, Svensson H.
    Psychopharmacology (Berl); 2001 Dec; 159(1):98-104. PubMed ID: 11797076
    [Abstract] [Full Text] [Related]

  • 6. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
    Lavian G, Finberg JP, Youdim MB.
    Clin Neuropharmacol; 1993 Dec; 16 Suppl 2():S1-7. PubMed ID: 8313392
    [Abstract] [Full Text] [Related]

  • 7. Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study.
    Colzi A, d'Agostini F, Kettler R, Borroni E, Da Prada M.
    J Neural Transm Suppl; 1990 Dec; 32():79-84. PubMed ID: 2089114
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reversal of stress-induced memory changes by moclobemide: the role of neurotransmitters.
    Nowakowska E, Chodera A, Kus K, Nowak P, Szkilnik R.
    Pol J Pharmacol; 2001 Dec; 53(3):227-33. PubMed ID: 11785923
    [Abstract] [Full Text] [Related]

  • 10. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
    Kumagae Y, Matsui Y, Iwata N.
    Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Burkard WP, Bonetti EP, Da Prada M, Martin JR, Polc P, Schaffner R, Scherschlicht R, Hefti F, Müller RK, Wyss PC.
    J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
    [Abstract] [Full Text] [Related]

  • 12. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M, Kettler R, Keller HH, Burkard WP, Haefely WE.
    J Neural Transm Suppl; 1989 Jan; 28():5-20. PubMed ID: 2677242
    [Abstract] [Full Text] [Related]

  • 13. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
    Gol'dina OA, Zagorevskiĭ VA, Lopatina KI, Sokolova TV, Gankina EM.
    Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
    [Abstract] [Full Text] [Related]

  • 14. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [Abstract] [Full Text] [Related]

  • 15. [A behavioral and neurochemical study on the mechanism of the anxiolytic effect of monoamine oxidase inhibitors].
    Maki Y.
    Hokkaido Igaku Zasshi; 2001 May; 76(3):133-42. PubMed ID: 11481866
    [Abstract] [Full Text] [Related]

  • 16. Metabolism and efflux of [3H]dopamine in rat neostriatum: presynaptic origin of 3,4-[3H]dihydroxyphenylacetic acid.
    Cubeddu LX, Hoffmann IS, Ferrari GB.
    J Pharmacol Exp Ther; 1979 May; 209(2):165-75. PubMed ID: 255152
    [No Abstract] [Full Text] [Related]

  • 17. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D, Bergis OE, Fankhauser C, Gardes A, Adam R, Charieras T, Grosset A, Rovei V, Jarreau FX.
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [Abstract] [Full Text] [Related]

  • 18. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
    Finberg JP.
    Acta Psychiatr Scand Suppl; 1995 Apr; 386():8-13. PubMed ID: 7717096
    [Abstract] [Full Text] [Related]

  • 19. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP, Galva MD, Villa F, Sciaba L, Picotti GB.
    Biochem Pharmacol; 1995 Jun 29; 50(1):97-102. PubMed ID: 7605351
    [Abstract] [Full Text] [Related]

  • 20. On the reversibility of reversible MAO inhibitors.
    Waldmeier PC.
    Naunyn Schmiedebergs Arch Pharmacol; 1985 May 29; 329(3):305-10. PubMed ID: 4022138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.